All News

11 December 2011

Micromet’s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma PatientsAntibodies

8 December 2011

Genentech Announces Positive Results of Pivotal Phase III Study with pertuzumab in HER2-Positive Metastatic Breast CancerAntibodies

7 December 2011

Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin ValortimAntibodies

7 December 2011

Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody ConferenceAntibodies

7 December 2011

Amgen and FDA Agree to Modify Nplate (Romiplostim) Risk Evaluation and Mitigation StrategyAntibodies

6 December 2011

Peregrine’s Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer TrialAntibodies

6 December 2011

MorphoSys Unveils Next-Generation Antibody Technology YlanthiaAntibodies

5 December 2011

Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual AcuityAntibodies

1 December 2011

Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC StudyAntibodies

1 December 2011

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid TumorsAntibodies

30 November 2011

ABLYNX REPORTS POSITIVE PHASE I DATA FOR ALX-0061 IN RHEUMATOID ARTHRITISAntibodies

29 November 2011

Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Antibodies

28 November 2011

Micromet Initiates Global Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAntibodies

28 November 2011

Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in ChinaAntibodies

24 November 2011

Tregalizumab (BT-061) shows efficacy in Chronic Plaque PsoriasisAntibodies

23 November 2011

Octapharma Reports octagam 5% and octagam 10% Global Sales Totaled 1.7 Million Grams Through October With No Thromboembolic EventsAntibodies

22 November 2011

Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for ReviewAntibodies

22 November 2011

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer TrialAntibodies

19 November 2011

Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung CancerAntibodies

19 November 2011

Regeneron Announces FDA Approval of EYLEA™ (Aflibercept) Injection for the Treatment of Wet Age-Related Macular DegenerationAntibodies

18 November 2011

FDA Commissioner announces Avastin decisionAntibodies

16 November 2011

The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate CancerAntibodies

15 November 2011

Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European UnionAntibodies

14 November 2011

ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP CompoundAntibodies

14 November 2011

Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple SclerosisAntibodies

11 November 2011

Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUSAntibodies

10 November 2011

ABLYNX REPORTS PHASE II DATA FOR ALX-0081 IN HIGH RISK ACS PATIENTS UNDERGOING A PCI PROCEDUREAntibodies

10 November 2011

XOMA Expands Gevokizumab (XOMA 052) ProgramAntibodies

10 November 2011

Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in HypercholesterolemiaAntibodies

9 November 2011

Alethia Biotherapeutics Announces Promising In Vivo Results for its EMT Inhibitor AB-16B5 and Issuance of a Patent for the Role of Secreted Clusterin in EMTAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

FcRn Inhibitors Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

TSLP Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends